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Introduction and background
===========================

Metastasis to the ovaries is common, and secondary tumors represent 7% to 15% of the ovarian neoplasms \[[@REF1]\]. The most common malignancies responsible for the secondary involvement of the ovaries include stomach, colon, breast, endocervix, endometrium, as well as lymphoma \[[@REF2]\]. In many cases, a known history of a primary neoplasm exists, but the ovarian mass is rarely the initial lesion \[[@REF3]\].

Among the different types of kidney carcinomas (KC), clear cell renal cell carcinoma (ccRCC) is the most common histotype. It usually metastasizes to the lungs, lymph nodes, bones, brain, liver \[[@REF2]\], and, very rarely, the ovary. According to our knowledge, fewer than 40 cases have been published in the English literature to date.

Papillary renal cell carcinoma (PRCC) and chromophobe renal cell carcinoma (ChRCC) account for 10% and 5% of the KC cases, respectively. They display an indolent behavior, remaining confined to the kidney \[[@REF4]\], while collecting duct carcinoma (CDC) \[[@REF5]\] and unclassified renal cell carcinoma (RCCU) \[[@REF6]\] are rare tumors with aggressive clinical behavior.

Using the keywords clear cell renal cell carcinoma, papillary renal cell carcinoma, chromophobe renal cell carcinoma collecting duct carcinoma, and ovarian metastasis, we reviewed reports of KC with ovarian metastasis via Google Scholar and PubMed indices in April 2018, including a case diagnosed in our department. Herein, we have reviewed the clinicopathological features, treatment, and outcome of the 41 KC cases with ovarian metastasis yielded by our search.

Review
======

KC metastasis to the ovary is a rare event. This can be explained by its male predominance with the male-to-female ratio being 2:1 \[[@REF7]\], low incidence of tumor emboli to the ovary, vascular sclerosis of the postmenopausal ovary when KC usually occurs, and the misdiagnoses of some metastatic tumors as primary ovarian neoplasms \[[@REF8]-[@REF9]\].

In the literature, several KC cases were not completely analyzed, with important data missing such as the type of surgical operation, adjuvant therapy, and sizes of the primary and metastatic tumors. The clinicopathological features of the cases, 36 ccRCC, two PRCC, one CDC, one ChRCC, and one RCCU, are presented in Table [1](#TAB1){ref-type="table"}. Patients' age ranged from 17 to 80 years (mean age: 53 years). The right kidney was involved in 20 and the left in 19 patients. Ovarian metastasis was ipsilateral in 13, contralateral in 15, and bilateral in 11 cases, including our case. According to the available data, primary tumor size ranged from 50 mm to 165 mm (mean value: 86 mm), whereas the size of the secondary tumor ranged from microscopic involvement to 180 mm (mean value: 100 mm). In two cases, there was tumor-to-tumor metastasis consisting of two small nodules in a mucinous cystadenoma \[[@REF10]\] in the first case and a multilocular cystic ovarian tumor consisting of mixed mucinous cystadenoma and Brenner tumor in the second one \[[@REF11]\].

###### Kidney carcinoma clinicopathological characteristics

NA: not available, SATh: systemic adjuvant therapy, HBSO: hysterectomy and bilateral salpingo-oophorectomy, BSO: bilateral salpingo-oophorectomy, RSO: right salpingo-oophorectomy, LSO: left salpingo-oophorectomy, LO: left oophorectomy, DOD: died of disease, AWD: alive with disease, ANED: alive no evidence of disease, ccRCC: clear cell renal cell carcinoma, ChRRC: chromophobe renal cell carcinoma, CDC: collecting duct carcinoma, PRCC: papillary renal cell carcinoma, RCCU: renal cell carcinoma unclassified.

\*Four patients in the Liang et al. series received chemotherapy. No more details were provided.

  ------ ----- ------- -------- ----------- --------- --------- ------------- ---------------------------------
  Year   Age   Type    Kidney   Ovary       Surgery   S.A.Th.   Outcome(mo)   Author
  1949   57    ccRCC   Left     Left        NA        No        DOD (18)      Martzlof et al. \[[@REF12]\]
  1957   64    ccRCC   Right    Bilateral   BSO       No        DOD (15)      Hobbs et al. \[[@REF13]\]
  1981   68    ccRCC   Right    Left        LO        No        ANED (25)     Stefani et al. \[[@REF14]\]
  1983   52    ccRCC   Left     Left        NA        No        Unknown       Buller et al. \[[@REF15]\]
  1992   48    ccRCC   Right    Left        LSO       No        AWD (96)      Young et al. \[[@REF16]\]
  1992   62    ccRCC   Left     Right       HBSO      No        AWD (6)       Young et al. \[[@REF16]\]
  1992   48    ccRCC   Left     Left        LSO       No        NA            Young et al. \[[@REF16]\]
  1992   28    ccRCC   Right    Left        NA        NA        NA            Liu et al. \[[@REF17]\]
  1993   40    ccRCC   Left     Bilateral   HBSO      No        AWD (55)      Spencer et al. \[[@REF18]\]
  1994   46    ccRCC   Left     Bilateral   HBSO      Yes       ANED (36)     Adachi et al. \[[@REF19]\]
  1996   54    ccRCC   Right    Left        NA        No        NA            Fields et al. \[[@REF8]\]
  1998   80    ccRCC   Right    Bilateral   HBSO      No        ANED (24)     Vara et al. \[[@REF20]\]
  2003   48    ccRCC   Left     Bilateral   HBSO      Yes       AWD (3)       Hammock et al. \[[@REF21]\]
  2003   50    ccRCC   Right    Right       HBSO      No        ANED (6)      Insabato et al. \[[@REF10]\]
  2003   49    ccRCC   Right    NA          NA        No        DOD (6)       Insabato et al. \[[@REF10]\]
  2003   17    ccRCC   Left     Left        NA        No        ANED (24)     Insabato et al. \[[@REF10]\]
  2004   61    ccRCC   Left     Bilateral   BSO       Yes       AWD (24)      Valappil et al. \[[@REF22]\]
  2004   79    CDC     Left     Left        No        No        DOD (\<1)     Kassouf et al. \[[@REF23]\]
  2006   52    ccRCC   Left     Right       BSO       Yes       DOD (10)      Kato et al. \[[@REF24]\]
  2007   73    PRCC    Right    Left        LSO       NA        NA            Stolnicu et al. \[[@REF25]\]
  2009   56    ccRCC   Right    Bilateral   HBSO      No        ANED (19)     Albrizio et al. \[[@REF26]\]
  2009   45    ccRCC   Right    Left        LO        Yes       AWD (48)      Anagnostou et al. \[[@REF27]\]
  2009   54    ccRCC   Left     Left        HBSO      No        DOD (9)       Toquero et al. \[[@REF7]\]
  2010   54    ccRCC   NA       Bilateral   HBSO      Yes       AWD (48)      Guney et al. \[[@REF28]\]
  2011   63    ccRCC   Right    ΝΑ          HBSO      No        AWD (132)     Decoene et al. \[[@REF29]\]
  2012   45    ccRCC   Left     Right       HBSO      Yes       NA            Udoji et al. \[[@REF30]\]
  2012   71    ccRCC   Right    Right       RSO       No        NA            Ibrahim et al. \[[@REF11]\]
  2014   61    ccRCC   Right    Bilateral   HBSO      Yes       ANED (12)     Bauerová et al. \[[@REF31]\]
  2015   55    ccRCC   Left     Left        HBSO      No        ANED (14)     Dolanbay et al. \[[@REF32]\]
  2015   51    ccRCC   Left     Right       HBSO      No        ANED (2)      Kostrzewa et al. \[[@REF9]\]
  2015   48    ccRCC   Right    Right       HBSO      No        NA            Bohara et al. \[[@REF33]\]
  2016   60    ccRCC   Right    Right       NA        \*        AWD (40)      Liang et al. \[[@REF34]\]
  2016   48    ccRCC   Left     Right       NA        \*        AWD (57)      Liang et al. \[[@REF34]\]
  2016   45    ccRCC   Right    Left        NA        \*        DOD (48)      Liang et al. \[[@REF34]\]
  2016   43    ccRCC   Right    Right       NA        \*        DOD (109)     Liang et al. \[[@REF34]\]
  2016   52    ccRCC   Left     Right       NA        \*        DOD (132)     Liang et al. \[[@REF34]\]
  2016   52    ccRCC   Right    Left        NA        \*        DOD (204)     Liang et al. \[[@REF34]\]
  2016   NA    ChRRC   xxx      NA          NA        \*        NA            Liang et al. \[[@REF34]\]
  2016   37    RCCU    Left     Bilateral   NA        \*        AWD (22)      Liang et al. \[[@REF34]\]
  2017   45    PRCC    Left     Left        HBSO      No        ANED (3)      Bashkar et al. \[[@REF35]\]
  2017   46    ccRCC   Right    Bilateral   HBSO      Yes       DOD (7)       Koufopoulos et al. \[[@REF36]\]
  ------ ----- ------- -------- ----------- --------- --------- ------------- ---------------------------------

Regarding the presenting symptoms, 11 patients were asymptomatic with metastasis found on scheduled postoperative imaging. Seven patients presented with an abdominal mass \[[@REF7],[@REF8],[@REF10],[@REF16],[@REF22],[@REF32]\], four with weight loss \[[@REF7],[@REF11],[@REF13],[@REF34]\], three with vaginal bleeding \[[@REF10],[@REF12],[@REF19]\], two with fever \[[@REF14],[@REF20]\], two with irregular menses \[[@REF18],[@REF21]\], two with an abdominal distension \[[@REF11],[@REF26]\], two with ascites \[[@REF8],[@REF15]\], abdominal pain \[[@REF20],[@REF36]\], weight gain \[[@REF15]\], fatigue \[[@REF13]\], weakness \[[@REF14]\], shortness of breath \[[@REF8],[@REF36]\], pelvic pain \[[@REF26]\], generalized malaise and decreased energy \[[@REF30]\], flank pain \[[@REF34]\], bone fracture \[[@REF24]\], and thyroid metastasis \[[@REF16]\]. In 26 patients, ovarian metastases were detected three months to 21 years after kidney involvement. In six cases, the primary cancer site and the metastasis were discovered concomitantly, while in four cases, the metastasis was detected first. In one case, ovarian metastasis was detected eight years before the primary tumor \[[@REF12]\]. Fuhrman grade was mentioned in 11 cases, including our case, four of them being grade 2, six grade 3, and a single case grade 4 with sarcomatoid features \[[@REF7],[@REF24],[@REF29],[@REF30],[@REF33]-[@REF34]\].

Clinical features such as cyst formation, size, and bilaterality did not help in differentiating primary from metastatic ovarian tumors \[[@REF37]\]. Histologically, the main differential diagnosis of metastatic ccRCC to the ovary was between ovarian clear cell carcinoma (OCCC), steroid cell tumor, dysgerminoma, and clear cell variant of struma ovarii \[[@REF10],[@REF21]\]. In cases of simultaneous presentation of kidney and ovarian tumor, ovarian metastasis to kidney and independent primaries have to be considered. There are three cases with independent primaries \[[@REF31]\] and four ovarian carcinomas metastatic to the kidney \[[@REF9]\] in the literature. Attention to histological differences between ccRCC and its ovarian mimics paired with clinical history were considered sufficient on several occasions.

Microscopically, both ccRCC and OCCC may have cystic, solid, tubular, and papillary areas. Tumor cells may display clear or eosinophilic cytoplasm and prominent nucleoli. In ccRCC, tumor cells usually lack significant pleomorphism (Figure [1a](#FIG1){ref-type="fig"}) and are characteristically associated with a prominent vascular network (Figure [1b](#FIG1){ref-type="fig"}) \[[@REF18],[@REF22]\]. In OCCC, tubular or glandular formations are lined by hobnail cells at least focally in almost 90% of cases \[[@REF20]\]. Tubules and cysts in OCCC may be filled with extracellular mucin \[[@REF18],[@REF20]\], a feature not present in ccRCC.

![(a) ccRCC tumor cells with moderately atypical nuclei lacking significant pleomorphism (H&E x 100). (b) On higher power magnification, a prominent, thin-walled vascular network is characteristic of ccRCC (H&E x 200).\
ccRCC: clear cell renal cell carcinoma, H&E: hematoxylin and eosin](cureus-0010-00000003620-i01){#FIG1}

Steroid cell tumors not otherwise specified are composed of lipid-rich tumor cells with clear intracytoplasmic vacuoles that are arranged in solid sheets, thin cords, or columns lacking the tubular differentiation of ccRCC which often contain intraluminal blood or colloid-like material \[[@REF10],[@REF21]\].

Dysgerminomas display a diffuse, trabecular, insular, or cordlike pattern. Tumor cells have large uniform round nuclei and clear cytoplasm. The stroma is filled with numerous mature lymphocytes \[[@REF21]\]. The clear cell variant of struma ovarii lacks the characteristic vascular pattern of ccRCC \[[@REF10]\].

In difficult cases when ovarian metastasis is the first presentation of the disease, immunohistochemistry can provide diagnostic solutions, and such an approach was followed in 11 of 35 published cases \[[@REF10]-[@REF11],[@REF21],[@REF26]-[@REF27],[@REF31]-[@REF34],[@REF36]\]. Among the most useful immunohistochemical markers are cluster of differentiation (CD)-10 (Figure [2a](#FIG2){ref-type="fig"}) and RCCma (Figure [2b](#FIG2){ref-type="fig"}). The immunohistochemical profile of ccRCC and its ovarian histological mimics is reported in Table [2](#TAB2){ref-type="table"}.

![(a) CD-10 is usually diffusely positive in ccRCC cells (CD-10 x 200). (b) Tumor cells showing positive staining for RCCma (RCCma x 200)\
ccRCC: clear cell renal cell carcinoma, RCCma: renal cell carcinoma marker](cureus-0010-00000003620-i02){#FIG2}

###### Immunophenotypic profile of clear cell tumors of the ovary

CK7: cytokeratin 7, EMA: epithelial membrane antigen, OCCC: ovarian clear cell carcinoma, ccRCC: clear renal cell carcinoma, PLAP: placental alkaline phosphatase, RCCma: renal cell carcinoma marker

  -------------------- ------- ----- ----- ------- ------- --------- ------ --------
                       AE1/3   CK7   EMA   CD-10   RCCma   Inhibin   PLAP   CD-117
  OCCC                 \+      \+    \+    \-      \-      \-        \-     \-
  Metastatic ccRCC     \+      \-    \+    \+      \+      \-        \-     \-
  Steroid cell tumor   \-      \-    \-    \-      \-      \+        \-     \-
  Dysgerminoma         \-      \-    \-    \-      \-      \-        \+     \+
  -------------------- ------- ----- ----- ------- ------- --------- ------ --------

In the literature, all 41 patients were treated surgically, 14 with hysterectomy and bilateral salpingo-oophorectomy (HBSO), four with bilateral salpingo-oophorectomy, two with left salpingo-oophorectomy (LSO), one with right salpingo-oophorectomy, and two with left oophorectomy. In 12 cases, no information concerning the type of surgical procedure was provided. Surgical treatment seems to offer a significant benefit in disease-free and overall survival (OS) in metastatic ccRCC. However, in the contemporary era of targeted therapy, cytoreductive nephrectomy or metastasectomy lacks proof of survival benefit with randomized trials \[[@REF38]\]. Furthermore, complete resection may be predictive of prolonged OS, along with the number of metastatic lesions (\>1 lesion), synchronous or asynchronous disease (\>1 year from nephrectomy to metastatic disease), site of metastases (pulmonary vs. extrapulmonary), and age (younger vs older than 60 years) \[[@REF39]-[@REF40]\].

Adjuvant therapy was reported in 12 patients in the literature. Eight patients received systemic therapy with interferon-a \[[@REF19],[@REF24]\], interleukin-2 \[[@REF22]\], a combination of interferon-a and sunitinib \[[@REF27]\], sunitinib \[[@REF28]\], and vinblastine \[[@REF31]\]. A patient started treatment with interleukin-2 and continued with a high dose of sunitinib after recurrence. Due to a lack of response, the regimen was altered to everolimus, resulting in no disease progression \[[@REF30]\]. In one case, the patient received three cycles of chemotherapy with no further specification \[[@REF21]\]. Liang et al. mention four patients receiving chemotherapy without providing more details \[[@REF34]\]. Systemic adjuvant therapy was used in our case \[[@REF36]\] consisting of the administration of sunitinib initially, later changed to sorafenib, which was stopped two months later due to intolerance and toxicity. Subsequently, pazopanib was administered showing a poor response, followed by nivolumab until the patient succumbed to the disease. Radiotherapy was mentioned in four cases, two of them as palliative therapy for bone \[[@REF7],[@REF29]\] and brain metastases \[[@REF9]\] and in one case for parotid gland, thyroid, and brain metastases \[[@REF18]\]. Follow-up was available in 28 patients with the longest period lasting 204 months. Ovarian metastasis is usually part of generalized disease with several patients also having metastases to other organs prior to, concurrently, or after ovarian involvement. The most frequent metastatic sites were, by descending order, bone in five cases \[[@REF7],[@REF10],[@REF17],[@REF24],[@REF30]\], lung in four cases \[[@REF7],[@REF13],[@REF24]\], abdomen in four cases \[[@REF10],[@REF13],[@REF22],[@REF30]\], adrenal glands in three cases \[[@REF27],[@REF34]\], skin in two cases \[[@REF18],[@REF22]\], muscle in two cases \[[@REF20],[@REF34]\], thyroid in two cases \[[@REF9],[@REF16]\], brain in two cases \[[@REF9],[@REF18]\]; and one metastasis to each of the following organs: parotid \[[@REF18]\], liver \[[@REF34]\], gallbladder \[[@REF29]\], vagina \[[@REF12]\], and cervical, pelvic, and paraaortic lymph nodes \[[@REF7],[@REF16],[@REF22]\]. In 12 cases, the ovary was the sole metastatic lesion described. Ten patients died of disease, nine patients were alive with no evidence of disease (ANED), and nine were alive with metastatic disease (AWD) in a period ranging from two months to 17 years (mean: 44 months).

Because there is no consistency in the data reported by different authors, no safe conclusions can be made regarding survival.

Two cases of PRCC ovarian metastasis were found in the literature. Patients' age ranged from 45 to 73 years (mean age: 59 years). The right and left kidneys were involved in one case each. Ovarian metastasis was ipsilateral in one case \[[@REF35]\] and contralateral in the second \[[@REF25]\]. The primary tumor size ranged from 85 to 106 mm (mean value: 95.5 mm), whereas the size of the metastatic lesion ranged from 60 to 117 mm (mean value: 88.5 mm). Patients presented with abdominal pain, constipation \[[@REF25]\], and abdominal mass \[[@REF35]\]. Ovarian metastasis was detected 36 months after kidney involvement \[[@REF25]\] and concomitantly \[[@REF35]\]. Fuhrman grade is mentioned in one case (grade 3). Simultaneous metastatic involvement was present in both cases in the para-aortic lymph nodes \[[@REF35]\] and anterior parietal peritoneum \[[@REF25]\]. Patients were treated with HBSO \[[@REF35]\] and LSO \[[@REF25]\]. No other clinical data concerning treatment or follow-up are referred \[[@REF25]\] in one case, whereas the other patient did not receive adjuvant therapy and was ANED three months after surgery \[[@REF35]\].

Histologically, PRCC may simulate papillary tumors from other locations, including the ovary such as in OCCC and ovarian serous carcinoma \[[@REF25],[@REF34]\]. In difficult cases, immunohistochemical staining may provide some help. Typical high-grade serous carcinoma is positive for Wilms\' tumor 1 (WT-1), and therefore negative staining for WT-1 favors metastatic carcinoma \[[@REF34]\].

A single case of metastatic ChRCC to the ovary is described in a case series \[[@REF34]\]. A patient with a history of ChRCC presented with bilateral ovarian metastases found on scheduled postoperative imaging. The tumor of the right ovary measured 150 mm, while the one of the left measured 55 mm. No other clinical data were available. ChRCC ovarian metastasis can mimic sex cord-stromal tumors. ChRCC will stain positive for CD-117 and negative for estrogen receptor, calretinin, and inhibin \[[@REF34]\].

A single case of metastatic CDC to the ovary was found in the English literature. A 79-year-old patient presented with symptoms of pyelonephritis and hypercalcemia. A radical nephrectomy was performed. High-grade malignant cells were found on frozen sections of the lymph nodes and psoas mass. There was also a large mass in the pelvis close to the primary tumor. Pathology showed a CDC. The patient had postoperative complications, dying 27 days after surgery. Metastatic disease to the left ovary was found at autopsy \[[@REF23]\]. CDC differentiation from primary ovarian carcinomas may be difficult due to overlapping histological features such as tubulopapillary architecture and hobnailing. Immunohistochemistry may provide little help with cytokeratin (CK)-903, CK-19, Ulex europaeus agglutinin lectin, and vimentin being positive in CDC \[[@REF5]\].

Histologically, it had a papillary architecture mimicking ovarian serous carcinoma and was immunopositive for paired box gene 8 (PAX8), vimentin, P504S, P53, and CK20 (focal) and negative for CK7, WT-1, high molecular weight cytokeratin and p63, CK5/6, CD10, and estrogen receptors, supporting the diagnosis of RCCU. There was also involvement of the omentum, peritoneum, and abdominal wall. The patient was AWD 22 months after surgery.

Conclusions
===========

Ovarian metastasis of KC occurs very rarely. Precise diagnosis may occasionally be challenging, but it is essential for the appropriate management. Immunohistochemistry will assist in most cases. Surgery seems to be an effective means to treat KC metastasis, offering a significant benefit in a disease-free and cancer-specific OS in retrospective studies so far. Adjuvant therapy offers significant benefit in disease control or palliation of symptoms.
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